In this article published in Drug Development & Delivery, Pascale Diesel and Lev Gerlovin discuss how as industry works to advance cell and gene therapy development, the debate over new approaches to structuring and financial clinical research continues.
Click here to read the article.
Why diabetes and other common health conditions matter for men on prostate cancer hormone therapy
Key takeaways Men with prostate cancer are more likely to die from heart disease, not cancer. Patients who start androgen deprivation therapy (ADT) are...